Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy
Open Access
- 19 July 2021
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 9 (7), 838
- https://doi.org/10.3390/biomedicines9070838
Abstract
A number of epidemiologic studies have demonstrated a strong association between increasing lipoprotein a [Lp(a)] and cardiovascular disease. This correlation was demonstrated independent of other known cardiovascular (CV) risk factors. Screening for Lp(a) in the general population is not recommended, although Lp(a) levels are predominantly genetically determined so a single assessment is needed to identify patients at risk. In 2019 ESC/EAS guidelines recommend Lp(a) measurement at least once a lifetime, fo subjects at very high and high CV risk and those with a family history of premature cardiovascular disease, to reclassify patients with borderline risk. As concerning medications, statins play a key role in lipid lowering therapy, but present poor efficacy on Lp(a) levels. Actually, treatment options for elevated serum levels of Lp(a) are very limited. Apheresis is the most effective and well tolerated treatment in patients with high levels of Lp(a). However, promising new therapies, in particular antisense oligonucleotides have showed to be able to significantly reduce Lp(a) in phase II RCT. This review provides an overview of the biology and epidemiology of Lp(a), with a view to future therapies.This publication has 69 references indexed in Scilit:
- New LDL-Cholesterol Lowering Therapies: Pharmacology, Clinical Trials, and Relevance to Acute Coronary SyndromesClinical Therapeutics, 2013
- Genetic Associations with Valvular Calcification and Aortic StenosisThe New England Journal of Medicine, 2013
- Association between high molecular weight apolipoprotein isoforms and lipoprotein levels in advanced chronic kidney disease and the effect of hemodialysisIndian Journal of Nephrology, 2013
- Lipoprotein(a): Cellular Effects and Molecular MechanismsCholesterol, 2012
- A Role for VEGFR2 Activation in Endothelial Responses Caused by Barrier Disruptive OxPAPC ConcentrationsPLOS ONE, 2012
- Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White SubjectsCirculation, 2012
- Proteomics of Lipoprotein(a) identifies a protein complement associated with response to woundingJournal of Proteomics, 2011
- Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart DiseaseThe New England Journal of Medicine, 2010
- Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual careTransfusion and Apheresis Science, 2010
- Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary DiseaseThe New England Journal of Medicine, 2009